Century Therapeutics (IPSC) Competitors $0.56 +0.04 (+8.18%) Closing price 04:00 PM EasternExtended Trading$0.56 +0.01 (+1.39%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC vs. CHRS, PLX, FBRX, SLS, MIST, ENTA, NLTX, PEPG, MCRB, and IPHAShould you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Coherus Oncology (CHRS), Protalix BioTherapeutics (PLX), Forte Biosciences (FBRX), SELLAS Life Sciences Group (SLS), Milestone Pharmaceuticals (MIST), Enanta Pharmaceuticals (ENTA), Neoleukin Therapeutics (NLTX), PepGen (PEPG), Seres Therapeutics (MCRB), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Century Therapeutics vs. Its Competitors Coherus Oncology Protalix BioTherapeutics Forte Biosciences SELLAS Life Sciences Group Milestone Pharmaceuticals Enanta Pharmaceuticals Neoleukin Therapeutics PepGen Seres Therapeutics Innate Pharma Century Therapeutics (NASDAQ:IPSC) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Which has more volatility and risk, IPSC or CHRS? Century Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Does the media refer more to IPSC or CHRS? In the previous week, Coherus Oncology had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Coherus Oncology and 2 mentions for Century Therapeutics. Coherus Oncology's average media sentiment score of 0.59 beat Century Therapeutics' score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IPSC or CHRS? Century Therapeutics currently has a consensus target price of $3.75, suggesting a potential upside of 575.31%. Coherus Oncology has a consensus target price of $4.51, suggesting a potential upside of 165.44%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Century Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Coherus Oncology 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has better valuation & earnings, IPSC or CHRS? Coherus Oncology has higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentury Therapeutics$6.59M7.28-$126.57M-$0.29-1.91Coherus Oncology$266.96M0.74$28.51M$1.551.10 Is IPSC or CHRS more profitable? Coherus Oncology has a net margin of 125.90% compared to Century Therapeutics' net margin of -19.10%. Coherus Oncology's return on equity of 0.00% beat Century Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Century Therapeutics-19.10% -11.53% -6.94% Coherus Oncology 125.90%N/A -34.85% Do insiders & institutionals hold more shares of IPSC or CHRS? 50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 5.0% of Century Therapeutics shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryCoherus Oncology beats Century Therapeutics on 10 of the 16 factors compared between the two stocks. Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPSC vs. The Competition Export to ExcelMetricCentury TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.34M$2.62B$6.16B$10.57BDividend YieldN/A56.38%5.66%4.69%P/E Ratio-1.9124.4085.5827.12Price / Sales7.28744.84612.62135.31Price / CashN/A28.3526.3031.10Price / Book0.295.3712.876.67Net Income-$126.57M$32.78M$3.30B$276.23M7 Day Performance11.15%3.90%4.80%3.31%1 Month Performance10.03%9.99%8.11%10.76%1 Year Performance-64.17%-3.12%75.85%33.58% Century Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPSCCentury Therapeutics2.4663 of 5 stars$0.56+8.2%$3.75+575.3%-66.9%$44.34M$6.59M-1.91170News CoverageAnalyst DowngradeGap UpHigh Trading VolumeCHRSCoherus Oncology4.2957 of 5 stars$1.70+13.3%$4.51+165.4%+57.7%$174.34M$272.21M1.10330PLXProtalix BioTherapeutics2.8571 of 5 stars$2.16+4.9%$15.00+594.4%+125.0%$172.22M$61.95M-16.62200Positive NewsGap UpFBRXForte Biosciences3.1099 of 5 stars$14.48+4.6%$68.00+369.6%+208.6%$172.07MN/A-0.895SLSSELLAS Life Sciences Group2.0827 of 5 stars$1.56-4.3%$7.00+348.7%+48.4%$171.63M$1M-4.8810Positive NewsShort Interest ↓MISTMilestone Pharmaceuticals2.4871 of 5 stars$2.03+1.5%$4.50+121.7%+40.7%$169.99M$1M-2.4230News CoveragePositive NewsENTAEnanta Pharmaceuticals3.9765 of 5 stars$15.16+91.9%$20.20+33.2%-9.5%$168.89M$67.64M-3.51160High Trading VolumeNLTXNeoleukin TherapeuticsN/A$17.82+2.4%N/A-54.0%$167.47MN/A-5.7390High Trading VolumePEPGPepGen3.8074 of 5 stars$4.64-8.5%$8.40+81.0%-44.8%$166.30MN/A-1.5730MCRBSeres Therapeutics2.4971 of 5 stars$18.69-1.3%$14.33-23.3%+21.3%$165.72M$126.32M-4.06330Positive NewsGap UpIPHAInnate Pharma2.6916 of 5 stars$1.82+2.0%$6.50+257.9%-5.0%$164.09M$21.77M0.00220Positive NewsGap Up Related Companies and Tools Related Companies CHRS Alternatives PLX Alternatives FBRX Alternatives SLS Alternatives MIST Alternatives ENTA Alternatives NLTX Alternatives PEPG Alternatives MCRB Alternatives IPHA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPSC) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
